References
- Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279 (2): 125-129.
- Pea F, Pavan F, Nascimben E, et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 2003; 47 (10): 3104-3108.
- Furlanut M, Brollo L, Lugatti E, et al. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 2003; 51 (1): 101-106.
- Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of levofloxacin 500 mg bid IV in ICU patients with earlyonset ventilator- associated pneumonia. Clin Pharmacokinet 2003; 42 (6): 589-598.
- Pea F, Pavan F, Di Qual E, et al. Urinary pharmacokinetics and theoretical pharmacodynamics of levofloxacin in ICU patients treated with 500 mg b.i.d. i.v. for ventilator associated pneumonia. J Chemother 2003; 15, 6: 563-567.
- Viale P, Pea F. What is the role of fluoroquinolones in intensive care? J Chemother 2003; 15, suppl. n. 3: 5-10.